The UK government has commissioned a review of AstraZeneca’s vaccine results, as reported by CNBC – an essential step to demonstrate safety, efficacy and quality. The review is being carried out by the UK’s independent medicines regulatory body.
Prior to the announcement by the British Ministry of Health, doubts about the design of the studies and the efficacy of the vaccine were increasingly raised. The Group had previously announced that an efficacy of around 90 percent could be achieved. There were no serious side effects. When the values from Phase I and II are added to those from Phase III, which had different dosage regimens, the average efficacy is 70 percent. The futurezone has reported.
These calculations caused scepticism. Some researchers substantiate that with an efficacy of 90 percent no test person was older than 55 years. Now the data are to be examined and provide for comprehensibleness. “We are working tirelessly to be in the best possible position to provide a vaccine as soon as it is approved by the independent regulatory body MHRA,” says Matt Hancock, the British Minister of Health.
AstraZeneca announced earlier this week that it would be initiating additional studies to complement the data from existing trials.
- hp with reports from futurezone.at. picture: pixabay.com
This post has already been read 667 times!